Grifols, S.A. (GRFS) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2023)
GRFS's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
By Geography
GRFS Revenue Analysis (2013–2024)
As of March 1, 2026, Grifols, S.A. (GRFS) generated trailing twelve-month (TTM) revenue of $7.52 billion, reflecting modest growth of +4.0% year-over-year. The most recent quarter (Q3 2025) recorded $1.87 billion in revenue, down 1.4% sequentially.
Looking at the longer-term picture, GRFS's 5-year compound annual growth rate (CAGR) stands at +7.2%, indicating steady revenue expansion. The company achieved its highest annual revenue of $7.21 billion in 2024, representing a new all-time high.
Revenue diversification analysis shows GRFS's business is primarily driven by Haemoderivatives (84%), Transfusional medicine (10%), and Other Product (3%). With over half of revenue concentrated in Haemoderivatives, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MRK (+1.3% YoY), PFE (-1.6% YoY), and GSK (+1.8% YoY), GRFS has underperformed the peer group in terms of revenue growth. Compare GRFS vs MRK →
Peer Comparison
Compare GRFS's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GRFSCurrent | $7.5B | +4.0% | +7.2% | 16.5% | |
| MRK | $65.0B | +1.3% | +9.4% | 41.2% | |
| PFE | $62.6B | -1.6% | +8.5% | 24.7% | |
| GSK | $32.0B | +1.8% | +5.6% | 21.9% | |
| SNY | $46.7B | +8.9% | +4.6% | 13.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $7.21B | +9.4% | $2.79B | 38.7% | $1.19B | 16.5% |
| 2023 | $6.59B | +8.7% | $2.48B | 37.7% | $782.3M | 11.9% |
| 2022 | $6.06B | +22.9% | $2.21B | 36.5% | $782.4M | 12.9% |
| 2021 | $4.93B | -7.6% | $1.96B | 39.8% | $595.1M | 12.1% |
| 2020 | $5.34B | +4.7% | $2.26B | 42.2% | $996.1M | 18.7% |
| 2019 | $5.10B | +13.6% | $2.34B | 45.9% | $1.13B | 22.2% |
| 2018 | $4.49B | +3.9% | $2.05B | 45.7% | $994.1M | 22.2% |
| 2017 | $4.32B | +6.6% | $2.15B | 49.8% | $1.00B | 23.2% |
| 2016 | $4.05B | +2.9% | $1.91B | 47.2% | $939.4M | 23.2% |
| 2015 | $3.93B | +17.3% | $1.93B | 49.1% | $970.4M | 24.7% |
See GRFS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GRFS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare GRFS vs AGIO
See how GRFS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is GRFS's revenue growth accelerating or slowing?
GRFS revenue growth slowed to +4.0%, below the 5-year CAGR of +7.2%. TTM revenue is $7.5B. The deceleration marks a shift from historical growth rates.
What is GRFS's long-term revenue growth rate?
Grifols, S.A.'s 5-year revenue CAGR of +7.2% reflects the variable expansion pattern. Current YoY growth of +4.0% is near this long-term average.
How is GRFS's revenue distributed by segment?
GRFS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.